{"filing":{"accession_number":"0001171843-26-005810","cik":"0001756594","ticker":"IVEVF","company_name":"Inventiva S.A.","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"f6k_083126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1756594/000117184326005810/f6k_083126.htm"},"events":[{"id":30718,"run_id":28161,"accession_number":"0001171843-26-005810","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The press release announces the appointment of Chris Benecchi as Chief Operating Officer of Inventiva, effective August 31, 2026. This is a clear executive appointment of a named officer to a C-suite role. The appointment is material because it occurs at a critical juncture—as the company approaches Phase 3 topline results for its lead candidate lanifibranor (expected Q4 2026) and prepares for potential commercialization in 2028—and Benecchi brings 30 years of biopharmaceutical leadership with direct experience in launch readiness and commercial operations.","company_name":"Inventiva S.A.","ticker":"IVEVF","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33406,"accession_number":"0001171843-26-005810","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Chris Benecchi as Chief Operating Officer of Inventiva, effective August 31, 2026. This is a clear executive appointment of a named officer to a C-suite role. The appointment is material because it occurs at a critical juncture—as the company approaches Phase 3 topline results for its lead candidate lanifibranor (expected Q4 2026) and prepares for potential commercialization in 2028—and Benecchi brings 30 years of biopharmaceutical leadership with direct experience in launch readiness and commercial operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:04:39.622223+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33406,"accession_number":"0001171843-26-005810","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Chris Benecchi as Chief Operating Officer of Inventiva, effective August 31, 2026. This is a clear executive appointment of a named officer to a C-suite role. The appointment is material because it occurs at a critical juncture—as the company approaches Phase 3 topline results for its lead candidate lanifibranor (expected Q4 2026) and prepares for potential commercialization in 2028—and Benecchi brings 30 years of biopharmaceutical leadership with direct experience in launch readiness and commercial operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T10:04:39.622223+00:00","company_name":"Inventiva S.A.","ticker":"IVEVF","filing_date":"2026-08-31"}]}